logo
Plus   Neg
Share
Email

Alnylam Expects To Exceed 2020 Goals With Four Marketed Products

Alnylam Pharmaceuticals Inc. (ALNY) said it expects to exceed its 2020 goals with four marketed products, 14 organic clinical stage programs, including 6 in late-stage development, across 4 strategic therapeutic areas, by end of 2020.

The company also announced that it has initiated HELIOS-B, a global Phase 3 placebo-controlled mortality and cardiovascular hospitalization trial with investigational vutrisiran in patients with ATTR amyloidosis with cardiomyopathy.

Alnylam also plans to support the Medicines company's continued efforts with respect to the ORION Phase 3 studies of inclisiran, an investigational RNAi therapeutic targeting PCSK9 in development for the treatment of hypercholesterolemia.

Alnylam also plans to support Sanofi's continued efforts in advancing fitusiran, an investigational RNAi therapeutic in development for the treatment of hemophilia.

Alnylam announced the selection of the initial seven programs in the Regeneron collaboration, including ALN-APP - an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for hereditary cerebral amyloid angiopathy (hCAA) and early onset familial Alzheimer's disease (EOFAD) - and ALN-HTT - an investigational RNAi therapeutic for the treatment of Huntington's disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
India-based Lupin Pharmaceuticals Inc. announced a recall of all batches of type 2 diabetes medication Metformin Hydrochloride Extended-Release Tablets, citing detection of N-Nitrosodimethylamine or NDMA, a probable human carcinogen. The move comes after many other drug companies called back Metformin tablets after the U.S. Food and Drug Administration or FDA recommended over NDMA concerns. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT